Latest Insider Transactions at Macrogenics Inc (MGNX)
This section provides a real-time view of insider transactions for Macrogenics Inc (MGNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MACROGENICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MACROGENICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2024
|
Scott Koenig President and CEO |
BUY
Bona fide gift
|
Indirect |
53,265
+11.08%
|
-
|
|
Oct 07
2024
|
Scott Koenig President and CEO |
SELL
Bona fide gift
|
Direct |
53,265
-100.0%
|
-
|
|
Sep 23
2024
|
Scott Koenig President and CEO |
BUY
Bona fide gift
|
Indirect |
374,215
+50.0%
|
-
|
|
Sep 23
2024
|
Scott Koenig President and CEO |
SELL
Bona fide gift
|
Direct |
374,215
-34.73%
|
-
|
|
May 20
2024
|
William K Heiden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
-
|
|
May 20
2024
|
Jay Philip Siegel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
-
|
|
May 20
2024
|
Edward Hurwitz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+10.7%
|
-
|
|
May 20
2024
|
Karen Jean Ferrante Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
-
|
|
May 20
2024
|
Meenu Chhabra Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
-
|
|
May 20
2024
|
Margaret Liu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
-
|
|
May 20
2024
|
Federica F. O'Brien Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
-
|
|
May 20
2024
|
David C Stump Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
-
|
|
May 20
2024
|
Scott Thomas Jackson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
-
|
|
Apr 04
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
51,395
-49.97%
|
$822,320
$16.58 P/Share
|
|
Apr 04
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
42,500
+45.26%
|
$170,000
$4.82 P/Share
|
|
Mar 06
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
19,625
-68.81%
|
$412,125
$21.5 P/Share
|
|
Mar 06
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,625
+29.48%
|
$196,250
$10.83 P/Share
|
|
Mar 04
2024
|
Eric Blasius Risser Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
41,159
-29.47%
|
$782,021
$19.82 P/Share
|
|
Mar 04
2024
|
Eric Blasius Risser Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+15.78%
|
$150,000
$10.15 P/Share
|
|
Mar 04
2024
|
James Karrels SVP, CFO and Secretary |
SELL
Open market or private sale
|
Direct |
30,000
-14.89%
|
$600,000
$20.5 P/Share
|
|
Mar 04
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
SELL
Open market or private sale
|
Direct |
10,000
-54.6%
|
$200,000
$20.0 P/Share
|
|
Mar 04
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+35.32%
|
$110,000
$11.5 P/Share
|
|
Feb 26
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
16,124
-64.45%
|
$274,108
$17.22 P/Share
|
|
Feb 22
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,366
-8.49%
|
$159,222
$17.11 P/Share
|
|
Feb 22
2024
|
Ezio Bonvini Sr VP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,125
+20.32%
|
-
|
|
Feb 22
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
10,126
-28.81%
|
$172,142
$17.11 P/Share
|
|
Feb 22
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
26,250
+42.76%
|
-
|
|
Feb 15
2024
|
Stephen L. Eck Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,872
-41.22%
|
$116,824
$17.4 P/Share
|
|
Feb 15
2024
|
Stephen L. Eck Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+50.0%
|
-
|
|
Feb 15
2024
|
Lynn Cilinski VP, Controller and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,378
-27.68%
|
$40,426
$17.4 P/Share
|
|
Feb 15
2024
|
Lynn Cilinski VP, Controller and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,668
+43.7%
|
-
|
|
Feb 15
2024
|
Scott Koenig President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,349
-1.31%
|
$243,933
$17.4 P/Share
|
|
Feb 15
2024
|
Scott Koenig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,341
+3.73%
|
-
|
|
Feb 15
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,441
-33.3%
|
$75,497
$17.4 P/Share
|
|
Feb 15
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,336
+50.0%
|
-
|
|
Feb 15
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,871
-6.67%
|
$99,807
$17.4 P/Share
|
|
Feb 15
2024
|
Ezio Bonvini Sr VP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+15.93%
|
-
|
|
Feb 15
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
5,020
-37.64%
|
$85,340
$17.4 P/Share
|
|
Feb 15
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
13,336
+50.0%
|
-
|
|
Feb 15
2024
|
James Karrels SVP, CFO and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,327
-2.58%
|
$90,559
$17.4 P/Share
|
|
Feb 15
2024
|
James Karrels SVP, CFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
15,003
+6.76%
|
-
|
|
Feb 15
2024
|
Eric Blasius Risser Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,879
-8.29%
|
$99,943
$17.4 P/Share
|
|
Feb 15
2024
|
Eric Blasius Risser Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+19.03%
|
-
|
|
Feb 07
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,334
-4.47%
|
$60,012
$18.0 P/Share
|
|
Feb 05
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
76,251
-85.66%
|
$1,220,016
$16.5 P/Share
|
|
Feb 05
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
76,251
+36.15%
|
$762,510
$10.83 P/Share
|
|
Feb 01
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
13,316
-15.13%
|
$199,740
$15.0 P/Share
|
|
Jan 19
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
13,316
-13.15%
|
$159,792
$12.0 P/Share
|
|
Dec 20
2023
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
18,880
-15.71%
|
$188,800
$10.08 P/Share
|
|
Oct 02
2023
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.49%
|
$600,000
$4.46 P/Share
|